Silvercrest Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.54M Sell
64,050
-3,373
-5% -$88.2K 0.01% 562
2026
Q1
$1.89M Sell
67,423
-9,371
-12% -$249K 0.01% 535
2025
Q4
$1.91M Sell
76,794
-63,671
-45% -$1.61M 0.01% 541
2025
Q3
$3.58M Sell
140,465
-4,531
-3% -$112K 0.02% 468
2025
Q2
$3.51M Sell
144,996
-8,710
-6% -$203K 0.02% 474
2025
Q1
$3.89M Sell
153,706
-3,934
-2% -$103K 0.03% 446
2024
Q4
$4.18M Sell
157,640
-512,779
-76% -$13.9M 0.03% 447
2024
Q3
$19.4M Sell
670,419
-26,937
-4% -$786K 0.13% 184
2024
Q2
$19.5M Sell
697,356
-71,214
-9% -$1.96M 0.13% 181
2024
Q1
$21.3M Sell
768,570
-8,515
-1% -$236K 0.14% 174
2023
Q4
$22.4M Sell
777,085
-131,390
-14% -$3.97M 0.16% 164
2023
Q3
$30.1M Sell
908,475
-797,788
-47% -$28.2M 0.23% 136
2023
Q2
$62.6M Sell
1,706,263
-352,856
-17% -$13.7M 0.45% 81
2023
Q1
$84M Sell
2,059,119
-67,286
-3% -$2.91M 0.64% 46
2022
Q4
$109M Buy
2,126,405
+27,012
+1% +$1.3M 0.84% 29
2022
Q3
$91.9M Sell
2,099,393
-34,719
-2% -$1.69M 0.76% 32
2022
Q2
$112M Buy
2,134,112
+54,185
+3% +$2.76M 0.85% 24
2022
Q1
$108M Buy
2,079,927
+23,694
+1% +$1.23M 0.7% 38
2021
Q4
$121M Sell
2,056,233
-2,186
-0.1% -$108K 0.77% 25
2021
Q3
$88.5M Sell
2,058,419
-40,155
-2% -$1.78M 0.6% 48
2021
Q2
$82.2M Sell
2,098,574
-22,966
-1% -$893K 0.54% 60
2021
Q1
$76.9M Buy
2,121,540
+35,779
+2% +$1.27M 0.52% 64
2020
Q4
$76.8M Sell
2,085,761
-97,889
-4% -$3.59M 0.56% 61
2020
Q3
$76M Sell
2,183,650
-7,457
-0.3% -$261K 0.65% 43
2020
Q2
$68M Buy
2,191,107
+22,465
+1% +$763K 0.6% 59
2020
Q1
$67.2M Buy
2,168,642
+478,889
+28% +$16.3M 0.72% 39
2019
Q4
$62.8M Buy
1,689,753
+15,196
+0.9% +$541K 0.49% 80
2019
Q3
$57.1M Sell
1,674,557
-21,699
-1% -$789K 0.47% 76
2019
Q2
$69.7M Sell
1,696,256
-12,081
-0.7% -$480K 0.65% 54
2019
Q1
$68.8M Sell
1,708,337
-980,051
-36% -$39.2M 0.68% 53
2018
Q4
$111M Sell
2,688,388
-651,068
-19% -$27M 1.23% 8
2018
Q3
$140M Buy
3,339,456
+2,121
+0.1% +$81.7K 1.27% 9
2018
Q2
$115M Sell
3,337,335
-158,905
-5% -$5.43M 1.08% 13
2018
Q1
$118M Buy
3,496,240
+45,344
+1% +$1.56M 1.15% 11
2017
Q4
$119M Buy
3,450,896
+286,650
+9% +$9.77M 1.1% 12
2017
Q3
$107M Buy
3,164,246
+144,680
+5% +$4.65M 1.07% 14
2017
Q2
$96.2M Buy
3,019,566
+9,911
+0.3% +$313K 1.03% 18
2017
Q1
$97.7M Buy
3,009,655
+67,867
+2% +$2.14M 1.05% 13
2016
Q4
$90.7M Buy
2,941,788
+145,856
+5% +$4.45M 1.02% 16
2016
Q3
$89.8M Buy
2,795,932
+49,156
+2% +$1.64M 1.08% 15
2016
Q2
$91.8M Buy
2,746,776
+917,534
+50% +$29.3M 1.17% 10
2016
Q1
$51.4M Buy
1,829,242
+490,142
+37% +$14M 0.71% 55
2015
Q4
$41M Buy
1,339,100
+1,021,079
+321% +$32.1M 0.57% 74
2015
Q3
$9.48M Sell
318,021
-128,023
-29% -$4.1M 0.14% 154
2015
Q2
$14.2M Buy
446,044
+118,862
+36% +$3.87M 0.19% 136
2015
Q1
$10.8M Sell
327,182
-4,500
-1% -$143K 0.15% 150
2014
Q4
$9.8M Buy
331,682
+1,581
+0.5% +$45.3K 0.14% 154
2014
Q3
$9.26M Sell
330,101
-4,663
-1% -$131K 0.14% 156
2014
Q2
$9.43M Buy
334,764
+7,733
+2% +$220K 0.14% 150
2014
Q1
$9.97M Sell
327,031
-8,739
-3% -$261K 0.16% 140
2013
Q4
$9.76M Sell
335,770
-3,102
-0.9% -$90.3K 0.16% 141
2013
Q3
$9.23M Buy
338,872
+2,691
+0.8% +$73.2K 0.18% 135
2013
Q2
$8.93M Buy
+336,181
New +$9.29M 0.19% 134

Other funds holding PFE

Silvercrest Asset Management's PFE Position: Q2 2026 in Review

Silvercrest Asset Management reduced its Pfizer (PFE) stake by 5% in Q2 2026, selling an estimated $88.2K and leaving 64,050 shares worth $1.54M. The position accounts for 0.01% of the portfolio, ranked #562.

Silvercrest Asset Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $140M in Q3 2018. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Silvercrest Asset Management held 64,050 shares of Pfizer worth $1.54M as of Q2 2026.
  • Silvercrest Asset Management sold 3,373 Pfizer shares in Q2 2026, an estimated $88.2K.
  • Pfizer made up 0.01% of Silvercrest Asset Management's portfolio in Q2 2026, its #562 holding.
  • Silvercrest Asset Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Silvercrest Asset Management's Pfizer position peaked at $140M in Q3 2018.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.